Evidence map›Paper›PMID 40002422›Full record

ReviewAntioxidants (Basel, Switzerland)2025

Pharmacological Mechanism and Drug Research Prospects of Ginsenoside Rb1 as an Antidepressant.

Shuhui Zhuang, Fuqiang Shi, Nazzareno Cannella, Massimo Ubaldi, Roberto Ciccocioppo, Hongwu Li, Di Qin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuhui ZhuangSchool of Chemical Engineering, Changchun University of Technology, Changchun 130012, China.
Fuqiang ShiSchool of Chemical Engineering, Changchun University of Technology, Changchun 130012, China.
Nazzareno CannellaPharmacology Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, Italy.
Massimo UbaldiPharmacology Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, Italy.ORCID 0000-0002-4089-2483
Roberto CiccocioppoPharmacology Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, Italy.ORCID 0000-0003-3126-9240
Hongwu LiSchool of Chemical Engineering, Changchun University of Technology, Changchun 130012, China.
Di QinDepartment of Geriatrics and General Practice, The Third Bethune Hospital of Jilin University, Changchun 130021, China.

Funding

Jilin Province Science and Technology Department JJKH20200688KJ
6 · The paper itself

Abstract

This review explores the antidepressant effects of ginsenoside Rb1, a natural compound in traditional Chinese medicine, and its potential for treating major depressive disorder (MDD). The aetiology of depression was reviewed up to 2024, focusing on the pathways and mechanisms through which ginsenoside Rb1 may exert its effects. Notably, ginsenoside Rb1 regulates oxidative stress and inflammatory processes while enhancing neural plasticity by downregulating miR-134 expression and alleviating depressive symptoms. Unlike traditional antidepressants that act on a single target, ginsenoside Rb1 interacts with multiple pathways, reflecting its potential for broader therapeutic application. To compensate for the current deficiency in animal experiments, clinical data, and research on the side effects of ginsenoside Rb1 in the treatment of depression, we reviewed some clinical data on the use of this component in the treatment of other diseases to explore its relevance to depression. Ginsenoside Rb1 is expected to serve as a novel antidepressant or as a complementary component in combination with other antidepressant compounds. However, further clinical trials and molecular studies are necessary to confirm its efficacy and potential side effects.

Indexed as

antidepressant mechanismsdepressionginsenoside Rb1inflammationmajor depressive disordernatural ingredients

Identifiers

PMID40002422
PMCPMC11851604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.